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Background: Liraglutide is a once-daily injectablemedication approved for the treatment
of obesity. Hereby we report the feasibility, adherence and efficacy of liraglutide treatment
in a sample of individuals with mood disorders and obesity.
Methods and Sample: Twenty-nine patients with Bipolar or Major Depressive Disorder
received liraglutide once daily subcutaneously at a dose gradually titrated from 0.6
to 3mg. All patients were obese and had previously failed multiple healthy lifestyle
interventions, including exercise and diet programs. Patients’ weight was recorded
before liraglutide treatment (T0) and then 1 (T1), 3 (T3), and 6 months (T6) following
T0.
Results: Mean baseline (T0) weight was 110.54Kg (±24.95). Compared to baseline,
the percentage of weight loss was 3.37% at T1, 7.85% at T3, and 10.20% at T6.
Thirty-one percent (n = 9) of patients had no side effects, 34.48% (n = 10) had one,
24.14% (n = 7) had two, and 10.34% (n = 3) had three side effects. All 29 subjects
were still on liraglutide at T1; 79.31 and 48.28% were on liraglutide at T3 and T6. No
significant relationship was found between liraglutide dose and likelihood to continue the
medication. No patient showed a worsening of the psychiatric condition due to liraglutide
treatment. Acceptability and satisfaction with treatment were good for the 48% that
completed the study.
Conclusions: Liraglutide treatment was efficacious, accepted and tolerated by ∼50%
of our sample, followed up for a period of 180 days. Larger, longer, controlled, prospective
studies are warranted.
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INTRODUCTION
Several studies have pointed to a link between cardiovascular diseases, obesity or metabolic
syndrome among patients suffering from severe psychiatric disorders (1).
For instance, patients suffering from depression, bipolar disorder and schizophrenia have 53%
higher chance of cardiovascular disease, comparing to persons without psychiatric disorders, and
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their life expectancy is decreased by at least one or two decades
(2). In addition, Weiner and associates found that the risk of
cardiovascular mortality is twice as larger among persons with
diagnosed bipolar disorder compared to general population (3).
The high prevalence of obesity, metabolic syndrome and
cardiovascular disease among patients diagnosed with major
psychiatric disorders may be a result of genetic factors,
inadequate lifestyles, such as poor dietary habits, lack of physical
activity and tobacco smoking, adverse effects of psychotropic
drugs, and environmental factor (4). Patients with psychiatric
diseases may also have poorer access to care, which may affect
the prevalence and severity of physical illnesses (5).
Liraglutide is an agonist of the acylated human Glucagon-
Like-Peptide-1 (GLP-1) receptor with 97% of sequence homology
with naturally produced GLP-1. This medication is the first once-
daily injectable derivative of the human incretin glucagon-like
peptide-1 recently approved by the European Medicines Agency
(EMA) and the United States Food and Drug Administration
(FDA) for the treatment of obesity (adults with a BMI ≥ 30
kg/m2), as well for adults with a BMI of 27 kg/m2 or greater
who also have one or more complications related to their weight,
such as type 2 diabetes, high blood pressure, high cholesterol or
obstructive sleep apnea (6, 7). Liraglutide reduces body weight
as well fatty mass through mechanisms that decrease the need
for food and energy intake. This agent also improves glycemic
control by reducing sugar levels in patients with type 2 diabetes
mellitus (8). Liraglutide stimulates the secretion of insulin and
reduces the excessive elimination of glucagon, based on glucose
concentration. When glucose level is high, insulin release is
stimulated and glucagon release inhibited. Conversely, during
hypoglycemia, liraglutide decreases the release of insulin, without
affecting glucagon release.
We recently reported on the development, acceptability
and efficacy of a standardized healthy lifestyle intervention in
recurrent unipolar and bipolar depression (9). Our lifestyle
intervention includes modules dealing with energy balance,
physical exercise, nutritional education and other strategies to
lose weight with physical exercise and to not relapse into
bad eating habits and sedentary life. Among other findings,
we observed a significant reduction in BMI in patients who
received the intervention, compared to controls. However, while
conducting the trial above, and during our daily practice, we
observed that–for a considerable number of patients- a lifestyle
behavioral intervention may not be sufficient to achieve the
necessary improvement in metabolic parameters. To this end,
we decided to test the feasibility, adherence, weight effects and
tolerability of liraglutide treatment, administered for a period of
6 months in a sample of patients with mood disorders.
MATERIALS AND METHODS
This was a retrospective study involving individuals with bipolar
or major depressive disorder who received liraglutide. All
study participants had previously failed multiple standardized
healthy lifestyle interventions, including physical exercise and
diet programs. Patients weight and BMI were registered at four
different time-points: baseline, i.e., when liraglutide was started
(T0), and then after 1 (T1), 3 (T2), and 6 months (T3).
Data were analyzed using STATA15 (Stat Corp., College
Station, Texas, USA). Descriptive statistics, Wilcoxon signed-
rank test and Fisher exact test were performed. The statistical
significance was set at level of 5% (p < 0.05). All study data was
collected retrospectively and no exam was specifically conducted
for the purposes of this study. For the reasons previously
mentioned, the study was exempt from informed consent. The
retrospective study was approved by the Regione Toscana–Area
Vasta Sud Est Ethical Committee Board.
RESULTS
Sample Characteristics
The sample included 29 patients diagnosed with mood disorders
and treated at University of Siena Medical Center, Italy. There
were almost four times more female patients (F = 80% of
the sample). Mean age was 53.48 ± 12.75 years and half of
participants (51.72) were employed. Twenty-one percent were
smokers. The vast majority was physically inactive and all
participants were obese. Four patients were in treatment with
second generation antipsychotics: 2 with risperidone, 1 with
olanzapine and 1 with aripiprazole. Hyperlipidemia and systolic
hypertension were the most frequent physical comorbidities
(Table 1).
Weight and BMI
At T1 (i.e., 1 month after liraglutide was started), a significant
weight loss was observed (p < 0.001) and the mean weight
decreased from 110.54 (±24.95) kg at baseline (T0) to 106.81
TABLE 1 | Sample characteristics.
Patients’ sociodemographic characteristics Frequency (%)
Total number of participants 29
Gender Female 23 (79.31)
Male 6 (20.69)
Marital Status Single 11 (37.93)
Married 18 (62.07)
Educational Background Primary/Middle School 8 (27.59)
High School Diploma 13 (44.83)
Bachelor 8 (27.59)
PATIENTS′ LIFESTYLE
Smoking tobacco 6 (20.69)
Physical activity 5 (17.24)
Diet Between meals 23 (79.31)
At meal time 6 (20.69)
PATIENTS′ BMI
Obesity Class I (BMI 30–34, 9 kg/m2 ) 4 (13,79)
Obesity Class II (BMI 35–39, 9 kg/m2 ) 25 (86,21)
PATIENTS′ COMORBIDITIES
Type 2 diabetes 6 (20.69)
Impaired glucose tolerance 7 (24.14)
Hyperlipidemia 16 (55.17)
Hypertension 13 (44.83)
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(±24.43) kg at T1 (Table 2). On average, patients lost 3.37%
of their baseline weight. Only two patients did not lose weight
in the first 1 month of treatment, and they both decided to
discontinue liraglutide. At the 3-month time point (T3), the
weight loss compared to baseline (T0) remained significantly
lower (p = 0.0001). Mean weight at T3 was (101.84 ± 17.92 kg)
(Table 2). On average, subjects lost 7.85% of their baseline
weight. Six patients discontinued liraglutide because of the
following reasons: pancreatic enzymes (lipase and amylase)
increase (n = 1), bariatric surgery (n = 1), no declared reason
(n = 1), treatment ineffectiveness (n = 2); lost to follow up
(n= 1).
At the 6 months’ time-point (T6) a significant weight loss
compared to baseline (T0) (p = 0.0010) was recorded as well.
Mean weight at T6 was 99.26 (±20.53) (Table 2). On average,
patients lost 10.2% of their baseline weight. However, only 14
patients, out of the original 29, were still taking liraglutide. The
reasons for discontinuation among 15 study participants who
did not complete 90 day of treatment were primarily due to
treatment ineffectiveness and/or undesirable side effects related
with liraglutide use.
Tolerability
The following undesirable side effects were recorded: amylase
and lipase increase, nausea, vomiting, diarrhea, and constipation.
Nine of the 29 patients (31%) reported no side effects, ten (34%)
reported one side effect, seven (24.14%) reported two side effects,
and 3 (10%) reported three side effects.
No significant relationship was observed between liraglutide
dose and number or severity of side effects. Similarly, no
relationship between physical comorbidities and side effects was
noted.
DISCUSSION
To our knowledge, only few studies have evaluated the feasibility
and safety of liraglutide treatment in patients with mood
disorders. For instance, Mansour and colleagues evaluated
the ability of liraglutide to improve cognitive function in 19
TABLE 2 | Weight, weight loss (%), BMI and BMI loss (%) of patients at T0, T1,
T3, and T6.
N Average weight ± SD (kg) % p
Baseline 29 110.54 (±24.95) – –
1 month (T1) 29 106.81 (±24.43) −3.37 p < 0.01
3 months (T3) 23 101.84 (±17.92) −7.85 p < 0.01
6 months (T6) 14 99.26 (±20.53) −10.20 p < 0.01
N Average BMI ± SD (kg/m2) %
Baseline 29 41.28 (±7.63) – –
1 month (T1) 29 39.90 (±7.22) −3.34 p < 0.01
3 months (T3) 23 40.65 (±11.43) −1.53 p < 0.01
6 months (T6) 14 38.4 (±6.57) −6.98 p < 0.01
N, Number of patients.
subjects with mood disorders and found that liraglutide was
well-tolerated and had beneficial effects on cognitive function.
The study was a 4-week pilot, open-label trial, and 17 of the
19 participating subjects completed the trial (10). In patients
with schizophrenia spectrum, Larsen et al. (11) conducted a
double-blind trial involving 103 overweight/obese individuals
who were prediabetic. Study subjects were randomized to a
16-week treatment with either liraglutide or placebo, while
receiving clozapine or olanzapine. Fifty-two individuals received
liraglutide. Five of these patients did not complete the 16-
week treatment, because of thyrotoxicosis (n = 1), worsening of
psychiatric disorder (n = 2), discontinuation or dose reduction
of olanzapine or clozapine (n = 2), death (n = 1). The
Authors showed that liraglutide treatment administered for 16
weeks significantly reduced glucometabolic disturbances and
body weight in overweight or obese and pre-diabetic patients
with schizophrenia-spectrum disorders, receiving clozapine or
olanzapine. Patients were then followed for 1 year after
discontinuing liraglutide. Although body weight reduction
was partially sustained, the improvements in other metabolic
variables returned to the levels that had been recorded before
starting the 16-week treatment with liraglutide (12). In our study,
liraglutide was continued for at least 6 months and proved
efficacious in about 50% of the study sample (14 out of 29)
whereas the remaining 50% discontinued the medication before
completing a 6 months treatment period, primarily because of
inefficacy or side effects. Among the latter, nine participants
asked to discontinue the medication (5 due to inefficacy; 4 due
side effects), five dropped out without presenting at the following
appointments, and one discontinued the treatment in agreement
with the treating physician (because of bariatric surgery). The
rate of persistence with liraglutide treatment was lower than
the rate observed in liraglutide trials involving subjects that
were not selected based on their psychiatric diagnosis (13,
14), this suggesting the possibility that patients with mood
disorders may be less likely to adhere to liraglutide treatment,
possibly because of their mental disorder. This rate was also
lower than the trials in patients with mental illness mentioned
above, which however were conducted in different settings
and for different periods. Nonetheless, we find it interesting
that ∼50% of our sample was able to tolerate, continue and
respond to liraglutide for a 6-month period. Neuropsychiatric
safety of treatment with liraglutide was evaluated pooling data
from the liraglutide weight-management programme, with no
between-treatment imbalances being noted for depression or
suicidal ideation/behavior (15). Consistently with this study,
no neuropsychiatric side-effects nor any liraglutide related
worsening of the pre-existing mental condition were noted in our
study. However, our research has several limitations that should
be acknowledged, including: (1) the small sample size, which
clearly does not permit to consider our sample as representative
of all patients with mood disorders; (2) the retrospective and
non-randomized design; (3) the absence of a placebo-control
group; (4) the relatively short duration (6 months) of the
observation period. Larger, longer, controlled, prospective trials
including measures of metabolic parameters, quality of life, daily
functioning and course of the psychiatric disease are warranted.
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